Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Jeffrey S MillerPhilip B McGlave


We previously demonstrated that autologous natural killer (NK)-cell therapy after hematopoietic cell transplantation (HCT) is safe but does not provide an antitumor effect. We hypothesize that this is due to a lack of NK-cell inhibitory receptor mismatching with autologous tumor cells, which may be overcome by allogeneic NK-cell infusions. Here, we test haploidentical, related-donor NK-cell infusions in a nontransplantation setting to determine safety and in vivo NK-cell expansion. Two lower intensity outpatient immune suppressive regimens were tested: (1) low-dose cyclophosphamide and methylprednisolone and (2) fludarabine. A higher intensity inpatient regimen of high-dose cyclophosphamide and fludarabine (Hi-Cy/Flu) was tested in patients with poor-prognosis acute myeloid leukemia (AML). All patients received subcutaneous interleukin 2 (IL-2) after infusions. Patients who received lower intensity regimens showed transient persistence but no in vivo expansion of donor cells. In contrast, infusions after the more intense Hi-Cy/Flu resulted in a marked rise in endogenous IL-15, expansion of donor NK cells, and induction of complete hematologic remission in 5 of 19 poor-prognosis patients with AML. These findings suggest that hap...Continue Reading


Jul 1, 1990·Immunology Today·H G Ljunggren, K Kärre
Jan 16, 1998·Immunity·M UhrbergP Parham
Mar 5, 1998·Nature·V M BraudA J McMichael
Jul 9, 1998·Immunity·L L LanierJ H Phillips
Jan 3, 2001·Blood·T A Fehniger, M A Caligiuri
May 9, 2001·Blood·T J FryC L Mackall
Aug 8, 2001·The Journal of Clinical Investigation·A N TheofilopoulosD H Kono
Oct 17, 2001·Experimental Hematology·J S Miller
Apr 18, 2002·Bone Marrow Transplantation·P LangD Niethammer
Jul 18, 2002·The Journal of Clinical Investigation·Gabriel N Maine, James J Mulé
Apr 16, 2003·The Journal of Experimental Medicine·Martin PrlicStephen C Jameson
Apr 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·William Larry GluckMaurice Wolin
Jan 25, 2005·Springer Seminars in Immunopathology·Roberto BaccalaArgyrios N Theofilopoulos

❮ Previous
Next ❯


Apr 12, 2007·Cancer Immunology, Immunotherapy : CII·Roberta CastriconiMaria Valeria Corrias
Mar 5, 2008·Cancer Immunology, Immunotherapy : CII·Karl-Johan MalmbergHans-Gustaf Ljunggren
Mar 29, 2008·Cancer Immunology, Immunotherapy : CII·Jinghai WenHing C Wong
Mar 5, 2009·Cancer Immunology, Immunotherapy : CII·Hyung-Ran KimJongsun Kim
Aug 4, 2010·Cancer Immunology, Immunotherapy : CII·Veronika BachanovaJeffrey S Miller
Aug 13, 2010·Cancer Immunology, Immunotherapy : CII·Eleni G IliopoulouSonia A Perez
Jan 18, 2011·Cancer Immunology, Immunotherapy : CII·Emilie P BuddinghArjan C Lankester
Jan 21, 2012·Breast Cancer Research and Treatment·Keiko KajitaniHideki Ohdan
Feb 8, 2011·Cancer Metastasis Reviews·Yuting MaLaurence Zitvogel
Mar 31, 2012·Frontiers of Medicine·Min ChengZhigang Tian
May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
May 7, 2010·Current Hematologic Malignancy Reports·Michael R Verneris, Michael J Burke
Dec 3, 2011·Clinical Reviews in Allergy & Immunology·Syh-Jae LinMing-Ling Kuo
Mar 16, 2005·Current Opinion in Immunology·Loredana RuggeriAndrea Velardi
Apr 4, 2013·Veterinary Immunology and Immunopathology·Dong-Jun ShinSang-Ki Kim
Jul 24, 2013·Veterinary Immunology and Immunopathology·Helen T MichaelJaime F Modiano
Aug 6, 2008·Bone Marrow Transplantation·H J Symons, E J Fuchs
Jun 19, 2012·Cellular & Molecular Immunology·Martha LuevanoAurore Saudemont
Apr 23, 2013·Cellular & Molecular Immunology·Min ChengZhigang Tian
Mar 26, 2013·Cellular & Molecular Immunology·Isabela Pedroza-PachecoAurore Saudemont
Dec 2, 2006·Nature Clinical Practice. Oncology·Pawel MuranskiNicholas P Restifo
Apr 22, 2008·Nature Immunology·Eric VivierSophie Ugolini
Feb 20, 2010·Nature Reviews. Cancer·Robert R Jenq, Marcel R M van den Brink
May 26, 2006·Nature Reviews. Immunology·Robert S Negrin, Christopher H Contag
Apr 18, 2007·Nature Reviews. Immunology·Hans-Gustaf Ljunggren, Karl-Johan Malmberg
Mar 23, 2012·Nature Reviews. Immunology·Eric VivierLaurent Brossay
Nov 21, 2007·Bone Marrow Transplantation·L J N Cooper
Nov 7, 2008·Proceedings of the National Academy of Sciences of the United States of America·Anna KruschinskiJehad Charo
Jun 30, 2009·Proceedings of the National Academy of Sciences of the United States of America·Caroline SolaSophie Ugolini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.